Phio Pharmaceuticals Corp.

For the period ended Dec 31, 2025. Filed Mar 5, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 5, 2026

PHIO$0.84+4.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

PART I. BUSINESS

Part I

Unless otherwise noted, (1) the term“Phio”* refers to Phio Pharmaceuticals Corp. and our subsidiary, MirImmune, LLC and (2)* the terms“Company,”* “we,” “us” and*“our”* refer to the ongoing business operations of Phio and MirImmune, LLC, whether conducted through Phio or MirImmune, LLC.*

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.